Integrating Next-Generation Sequencing into von Willebrand Disease Diagnostics: Insights from the PCM-EVW-ES Multicenter Project
Seminars in Thrombosis and Hemostasis · 2026-10 · 52 (07) · 869-880
DOI: 10.1055/a-2845-0281 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Thrombosis and Hemostasis, online erschienen am 15.04.2026. Verfasst von Nina Borràs und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratori de Coagulopaties Congènites, Banc de Sang i Teixits, Barcelona, Spain. Hauptthemen laut MEDLINE: von Willebrand Diseases, High-Throughput Nucleotide Sequencing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 75 Literaturangaben.
Abstract (Originalsprache)
Von Willebrand disease (VWD) is the most common inherited bleeding disorder, caused by quantitative or qualitative defects in von Willebrand factor (VWF). Diagnosis is challenging and requires integrating bleeding history, VWF antigen and activity measurements, FVIII assays, and specialized phenotyping. Genetic testing is increasingly recognized as a key component. Here, we review current concepts in VWD diagnostics and highlight the Spanish Clinical and Molecular Profile of von Willebrand Disease (PCM-EVW-ES) project as a model for genomics-enabled precision medicine. PCM-EVW-ES is a multicenter initiative involving 48 hospitals, centralized phenotypic testing, and next-generation sequencing of the VWF coding region, enabling definitive classification in 730 individuals with VWD to date. Harmonized recruitment criteria and standardized workflows improve subtype assignment, uncover complex genotypes, refine genotype–phenotype correlations, and facilitate the identification of asymptomatic carriers. The PCM-EVW-ES variant spectrum highlights recurrent disease-causing variants in Spain and underscores the value of coordinated national registries for variant curation. Building on these data, we propose a diagnostic algorithm in which bleeding assessment and first-line VWF/FVIII assays, combined with, early VWF molecular testing increases diagnostic accuracy and guides targeted second-line investigations to confirm and refine VWD subtype classification. We also outline persisting challenges, including the interpretation of variants of uncertain significance and patients without identifiable pathogenic VWF variants, and future directions integrating third-generation sequencing, expanded gene panels, functional studies, and artificial-intelligence-driven multiomic approaches. Together, these advances illustrate how robust multicenter studies can bridge the gap between complex diagnostics and clinical practice in VWD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratori de Coagulopaties Congènites, Banc de Sang i Teixits, Barcelona, Spain.
- Medicina Transfusional, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona (VHIR-UAB), Barcelona, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III (ISCIII), Spain.
Zitieren
APA
Borràs, N., Corrales, I., Vidal, F., & PCM-EVW-ES Investigators Team (2026). Integrating Next-Generation Sequencing into von Willebrand Disease Diagnostics: Insights from the PCM-EVW-ES Multicenter Project. Seminars in Thrombosis and Hemostasis, 52(07), 869-880. https://doi.org/10.1055/a-2845-0281
Vancouver
Borràs N, Corrales I, Vidal F, PCM-EVW-ES Investigators Team. Integrating Next-Generation Sequencing into von Willebrand Disease Diagnostics: Insights from the PCM-EVW-ES Multicenter Project. Seminars in Thrombosis and Hemostasis. 2026;52(07):869-880. doi:10.1055/a-2845-0281
BibTeX
@article{Borrs2026,
author = {Borràs, Nina and Corrales, Irene and Vidal, Francisco and PCM-EVW-ES Investigators Team, PCM-EVW-ES Investigators Team},
title = {Integrating Next-Generation Sequencing into von Willebrand Disease Diagnostics: Insights from the PCM-EVW-ES Multicenter Project},
journal = {Seminars in Thrombosis and Hemostasis},
year = {2026},
volume = {52},
number = {07},
pages = {869--880},
doi = {10.1055/a-2845-0281}
}
EUVIMED